Ultimately I have chosen to vote Yes, however in the meantime will keep it as a no to inspire another increase from Pfizer. If no additional announcements get made prior to kick off of any further increases to their offer; I will be changing my vote to Yes just before it counts.
I have no faith that our board can truly commercialise the technology and don't believe they will ever be able to steer RAP into a "going concern" as a business given cash burn rate and minimal revenue which if we are being honest with ourselves has been atrocious given the time-span they've had to make it happen. The BOD pay themselves more than what the company is able to generate and it isn't a sustainable business model to continue to do CR at investors' continual expenses.
Time to take off those rose-tinted glasses.
- Forums
- ASX - By Stock
- RAP
- Ann: Dispatch of Supplementary Scheme Booklet
Ann: Dispatch of Supplementary Scheme Booklet, page-10
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online